{"id":"NCT04082364","sponsor":"MacroGenics","briefTitle":"Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer","officialTitle":"A Phase 2/3 Trial to Evaluate Margetuximab in Combination With INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in Patients With Metastatic or Locally Advanced, Treatment-naïve, HER2-Positive Gastric or Gastroesophageal Junction Cancer","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2019-09-30","primaryCompletion":"2024-01-15","completion":"2025-03-25","firstPosted":"2019-09-09","resultsPosted":"2025-04-22","lastUpdate":"2025-06-08"},"enrollment":82,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Gastric Cancer","Gastroesophageal Junction Cancer","HER2-positive Gastric Cancer"],"interventions":[{"type":"BIOLOGICAL","name":"margetuximab","otherNames":["MGAH22","Margenza®"]},{"type":"BIOLOGICAL","name":"Retifanlimab","otherNames":["MGA012","INCMGA00012"]},{"type":"BIOLOGICAL","name":"Tebotelimab","otherNames":["MGD013"]},{"type":"BIOLOGICAL","name":"Trastuzumab","otherNames":["Herceptin"]},{"type":"OTHER","name":"Chemotherapy","otherNames":[]}],"arms":[{"label":"Chemotherapy-free arm","type":"EXPERIMENTAL"},{"label":"Margetuximab, retifanlimab, and chemotherapy arm","type":"EXPERIMENTAL"},{"label":"Margetuximab, tebotelimab and chemotherapy arm","type":"EXPERIMENTAL"},{"label":"Margetuximab and chemotherapy arm","type":"EXPERIMENTAL"},{"label":"Trastuzumab and chemotherapy arm","type":"ACTIVE_COMPARATOR"}],"summary":"This is a Phase 2/3, randomized, open-label study for the treatment of patients with HER2-positive Gastric cancer (GC) or Gastroesophageal Junction (GEJ) cancer conducted in two parts.\n\nPart A is a single-arm cohort (Cohort A, 40 to 110 participants) will evaluate safety and efficacy of margetuximab plus retifanlimab.\n\nPart B Part 1 has 4 arms (50 patients/arm). Participants will be randomized to margetuximab plus retifanlimab plus chemotherapy, margetuximab plus tebotelimab, plus chemotherapy, margetuximab plus chemotherapy, or trastuzumab plus chemotherapy.","primaryOutcome":{"measure":"Number of Participants With Adverse Events of Margetuximab Plus Retifanlimab in Cohort A, as Assessed by CTCAE v5.0","timeFrame":"Throughout the study, an average of 11 months.","effectByArm":[{"arm":"Chemotherapy-free Arm","deltaMin":47,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":4},"locations":{"siteCount":73,"countries":["United States","China","Germany","Italy","Poland","Singapore","South Korea","Taiwan","United Kingdom"]},"refs":{"pmids":["33263418"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":20,"n":48},"commonTop":["Anaemia","Diarrhoea","Platelet count decreased","Neutrophil count decreased","Nausea"]}}